KINIKSA PHARMACEUTICALS-A (KNSA)
BMG5269C1010 - Common Stock
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiniksa Pharmaceuticals (NASDAQ:KNSA) just reported results for the first quart...
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue...
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call...
Kiniksa Pharmaceuticals (KNSA) Shares Cross Above 200 DMA
Kiniksa Pharmaceuticals Becomes Oversold (KNSA)
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate...
(NASDAQ:KNSA)
Kiniksa Pharmaceuticals beats earnings expectations in Q4 2023, with a GAAP EPS of $0.35 and revenue of $83.4M.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to...
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual...
The 3 Most Undervalued Biotech Stocks to Buy in December
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Commit To Buy Kiniksa Pharmaceuticals At $10, Earn 4.7% Annualized Using Options
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Kiniksa Pharmaceuticals GAAP EPS of -$0.20 misses by $0.03, revenue of $67.05M beats by $2.6M (NASDAQ:KNSA)
Kiniksa Pharmaceuticals reports Q3 financial results: GAAP EPS misses by $0.03, but revenue beats estimates.
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid...
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Commit To Buy Kiniksa Pharmaceuticals At $15, Earn 14.7% Annualized Using Options
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Dynavax Technologies Stock Sees Renewed Technical Strength
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday
The company reported a big jump in revenue and updated guidance.
Kiniksa Pharmaceuticals GAAP EPS of $0.21 beats by $0.38, revenue of $71.47M beats by $19.27M (NASDAQ:KNSA)
Kiniksa Pharmaceuticals press release (KNSA): Q2 GAAP EPS of $0.21 beats by $0.38.Revenue of $71.47M (+165.0% Y/Y) beats by $19.27M.Total revenue for the second quarter of 2023...
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2023 net product revenue of $54.5 million –– ARCALYST 2023 net product revenue guidance increased to $220 - $230 million,...